Sodji Quaovi H, Gutkin Paulina M, Swetter Susan M, Reddy Sunil A, Hiniker Susan M, Knox Susan J
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Melanoma Manag. 2020 Feb 12;7(1):MMT36. doi: 10.2217/mmt-2019-0020.
We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term update on patients with complete response (CR) or partial response (PR).
PATIENTS & METHODS: We continued to follow these patients with serial imaging including computed tomography, PET or MRI.
Two of the three patients with CR are still alive and without evidence of melanoma but with chronic treatment-induced hypophysitis. The third patient died of hepatocellular carcinoma, but with no evidence of melanoma. Among the three patients with PR, two achieved CR after pembrolizumab monotherapy.
This long-term follow up reveals the striking durability of the CRs, which appears to correlate with a grade 2-3 hypophysitis.
我们之前报道了一项前瞻性试验，评估伊匹单抗与放射治疗联合应用于转移性黑色素瘤患者的安全性和疗效。在此，我们提供完全缓解（CR）或部分缓解（PR）患者的长期随访情况。
我们通过计算机断层扫描、PET或MRI等系列成像继续对这些患者进行随访。
3例CR患者中有2例仍存活，无黑色素瘤证据，但有慢性治疗引起的垂体炎。第3例患者死于肝细胞癌，但无黑色素瘤证据。在3例PR患者中，2例在帕博利珠单抗单药治疗后达到CR。
这项长期随访揭示了CR的显著持久性，这似乎与2-3级垂体炎相关。
